Johnson & Johnson looking to buy Ollin Biosciences for up to US$3.4bil
NEW YORK: Johnson & Johnson is poised to buy privately held eye disease drug developer Ollin Biosciences for up to US$3.4 billion, the Financial Times reported on Sunday, citing people familiar with the matter.
We haven't written up this one. New Straits Times has the full story — the link below goes straight to it.